The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE.
Publication
, Journal Article
Shah, NP; Wang, Q; Wolski, KE; Cho, L; McErlean, E; Ruotolo, G; Weerakkody, G; Riesmeyer, JS; Nicholls, SJ; Lincoff, AM; Nissen, SE; Menon, V
Published in: Diabetes Care
February 2020
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Diabetes Care
DOI
EISSN
1935-5548
Publication Date
February 2020
Volume
43
Issue
2
Start / End Page
e22 / e24
Location
United States
Related Subject Headings
- Endocrinology & Metabolism
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Shah, N. P., Wang, Q., Wolski, K. E., Cho, L., McErlean, E., Ruotolo, G., … Menon, V. (2020). The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. Diabetes Care, 43(2), e22–e24. https://doi.org/10.2337/dc19-1117
Shah, Nishant P., Qiuqing Wang, Katherine E. Wolski, Leslie Cho, Ellen McErlean, Giacomo Ruotolo, Govinda Weerakkody, et al. “The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE.” Diabetes Care 43, no. 2 (February 2020): e22–24. https://doi.org/10.2337/dc19-1117.
Shah NP, Wang Q, Wolski KE, Cho L, McErlean E, Ruotolo G, et al. The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. Diabetes Care. 2020 Feb;43(2):e22–4.
Shah, Nishant P., et al. “The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE.” Diabetes Care, vol. 43, no. 2, Feb. 2020, pp. e22–24. Pubmed, doi:10.2337/dc19-1117.
Shah NP, Wang Q, Wolski KE, Cho L, McErlean E, Ruotolo G, Weerakkody G, Riesmeyer JS, Nicholls SJ, Lincoff AM, Nissen SE, Menon V. The Role of Lipoprotein (a) as a Marker of Residual Risk in Patients With Diabetes and Established Cardiovascular Disease on Optimal Medical Therapy: Post Hoc Analysis of ACCELERATE. Diabetes Care. 2020 Feb;43(2):e22–e24.
Published In
Diabetes Care
DOI
EISSN
1935-5548
Publication Date
February 2020
Volume
43
Issue
2
Start / End Page
e22 / e24
Location
United States
Related Subject Headings
- Endocrinology & Metabolism
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences